2024
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia
Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.Peer-Reviewed Original ResearchQuality-adjusted life yearsCompletion of consolidation therapyFLT3-mutant acute myeloid leukemiaAllogeneic hematopoietic cell transplantationIncremental cost-effectiveness ratioProbabilistic sensitivity analysesImproved overall survivalHematopoietic cell transplantationPartitioned survival analysis modelAcute myeloid leukemiaCost-effectiveness ratioFLT3 inhibitor quizartinibHealth economic implicationsConsolidation therapyInduction chemotherapyAverage wholesale priceOverall survivalCell transplantationContinuous therapyMyeloid leukemiaITD mutationQuizartinibIncremental costCost-effective optionLife years
2020
Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis
Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal Of Geriatric Oncology 2020, 11: 1285-1292. PMID: 32513568, PMCID: PMC8721742, DOI: 10.1016/j.jgo.2020.05.013.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsMultiple myelomaTreatment optionsPhase II/IIICumulative ranking (SUCRA) probabilitiesFirst-line treatmentHematopoietic cell transplantationTerms of efficacyRandom-effects modelEfficacious regimensFrailty biomarkersFrontline regimensThalidomide maintenanceEffective regimensGeriatric assessmentLine treatmentTreatment regimensCell transplantationMeeting libraryIndividual patientsToxicity profileRegimensPatientsSystematic reviewRanking probability